Molecular Diagnostics in Rheumatoid Arthritis (MODIRA) cohort: Validation of predictive tools for prognosis and treatment strategies in rheumatoid arthritis, a multi-centre cohort study
Completed
- Conditions
- rheumatoid arthritis1000381610023213
- Registration Number
- NL-OMON45651
- Lead Sponsor
- Jan van Breemen Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Patients with established rheumatoid arthritis who are starting treatment with a biological (anti-TNFa, anti-IL-6,B cel inhibition or anti-costimulatory therapie)
Exclusion Criteria
patients with another rheumatological disease, that requires treatment with a biological
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Validation of prognostic tests, based on serological, cellular and molecular<br /><br>markers, as well as several imaging techniques, to predict the response to<br /><br>treatment and to predict disease severity and joint damage</p><br>
- Secondary Outcome Measures
Name Time Method <p>Cost effectiveness of (combinations of) in vitro tests in predicting response<br /><br>to biological treatment compared to existing<br /><br>tests such as RF and aCCP</p><br>